{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:07:48Z","timestamp":1779293268395,"version":"3.51.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"publisher","award":["82200215"],"award-info":[{"award-number":["82200215"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"publisher","award":["82170193"],"award-info":[{"award-number":["82170193"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"publisher","award":["82170194"],"award-info":[{"award-number":["82170194"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"publisher","award":["82370197"],"award-info":[{"award-number":["82370197"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2022-I2M-1-022"],"award-info":[{"award-number":["2022-I2M-1-022"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-2024AZ(BTK)ZD--0074"],"award-info":[{"award-number":["Y-2024AZ(BTK)ZD--0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chronic lymphocytic leukemia (CLL) is considerably more common in Americans compared with Asians. The basis for these differences and implications for therapy outcomes are controversial and mostly unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We compared baseline co-variates, therapies, and outcomes from 2 databases, Flatiron Health database in the United States (N\u2005=\u200515\u00a0786) and Tianjin CAMS database from China (N\u2005=\u20052996).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Chinese subjects had younger age at diagnosis, more advanced Rai stage and an increased prevalence of lymphadenoma, thrombocytopenia, and increased \u03b22-microglobulin. Americans had higher rates of unmutated IGHV, TP53 deletion, and cytogenetic abnormalities. These differences persisted after adjusting for age, Rai stage, and IGHV mutation state. There were also substantial differences in therapy patterns between the cohorts. Median survival in Chinese was 9.7 vs 7.5 years in Americans (P\u2005&amp;lt;\u2005.001). In sub-group analyses, Chinese CLL had better 5-year survivals with chemotherapy (69% [95% CI, 66, 72%] vs 49% [47, 52%]; P\u2005&amp;lt;\u2005.001), immune therapies (67% [63, 72%] vs 65% [64, 66%]; P\u2005=\u2005.041), and targeted therapies (85% [81, 88%] vs 65% [64, 67%]; P\u2005&amp;lt;\u2005.001). These advantages were pronounced among older patients and those with early-stage, mutated IGHV and without TP53 deletion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This cross-sectional study identifies significant clinical and treatment outcome disparities in CLL between Eastern and Western populations, attributed to distinct genetic and molecular profiles.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf181","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T19:12:42Z","timestamp":1751137962000},"source":"Crossref","is-referenced-by-count":5,"title":["Comparative analysis of patients\u2019 characteristics, treatment, and survival outcomes in CLL from China and the United States"],"prefix":"10.1093","volume":"30","author":[{"given":"Yuting","family":"Yan","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Tianjin 300052 ,","place":["People\u2019s Republic of China"]},{"name":"Tianjin Institutes of Health Science , Tianjin 300072 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7515-1843","authenticated-orcid":false,"given":"Yin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Public Administration, China Pharmaceutical University , Jiangning Campus, Nanjing 210029 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonglu","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Key Laboratory of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine , Nanjing 210029 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Public Administration, China Pharmaceutical University , Jiangning Campus, Nanjing 210029 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Public Administration, China Pharmaceutical University , Jiangning Campus, Nanjing 210029 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Public Administration, China Pharmaceutical University , Jiangning Campus, Nanjing 210029 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Tianjin 300052 ,","place":["People\u2019s Republic of China"]},{"name":"Tianjin Institutes of Health Science , Tianjin 300072 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Xiong","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Tianjin 300052 ,","place":["People\u2019s Republic of China"]},{"name":"Tianjin Institutes of Health Science , Tianjin 300072 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Tianjin 300052 ,","place":["People\u2019s Republic of China"]},{"name":"Tianjin Institutes of Health Science , Tianjin 300072 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Tianjin 300052 ,","place":["People\u2019s Republic of China"]},{"name":"Tianjin Institutes of Health Science , Tianjin 300072 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-9151","authenticated-orcid":false,"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Tianjin 300052 ,","place":["People\u2019s Republic of China"]},{"name":"Tianjin Institutes of Health Science , Tianjin 300072 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J","family":"Kipps","sequence":"additional","affiliation":[{"name":"Department of Medicine, UC San Diego Moores Cancer Center, University of California, San Diego , San Diego, CA 92093 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[{"name":"Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London , London SW7 2AZ ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Key Laboratory of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine , Nanjing 210029 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2590-8667","authenticated-orcid":false,"given":"Jifang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Public Administration, China Pharmaceutical University , Jiangning Campus, Nanjing 210029 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6291-812X","authenticated-orcid":false,"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Tianjin 300052 ,","place":["People\u2019s Republic of China"]},{"name":"Tianjin Institutes of Health Science , Tianjin 300072 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2025071610113972900_CIT0001","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/ajh.21824","article-title":"Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification","volume":"85","author":"Yoon","year":"2010","journal-title":"Am J Hematol"},{"key":"2025071610113972900_CIT0002","first-page":"65","article-title":"Incidence survey of leukemia in China","volume":"6","author":"Yang","year":"1991","journal-title":"Chin Med Sci J"},{"key":"2025071610113972900_CIT0003","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3109\/10428194.2013.827785","article-title":"Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008","volume":"55","author":"Mak","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2025071610113972900_CIT0004","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"Chihara","year":"2014","journal-title":"Br J Haematol"},{"key":"2025071610113972900_CIT0005","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12938-021-00973-6","article-title":"The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019","volume":"21","author":"Yao","year":"2022","journal-title":"Biomed Eng Online"},{"key":"2025071610113972900_CIT0006","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0145-2126(00)00038-2","article-title":"Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County","volume":"24","author":"Gale","year":"2000","journal-title":"Leuk Res"},{"key":"2025071610113972900_CIT0007","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/joim.12911","article-title":"The role of HLA variation in lymphoma aetiology and survival","volume":"286","author":"Zhong","year":"2019","journal-title":"J Intern Med"},{"key":"2025071610113972900_CIT0008","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/bjh.12366","article-title":"rs2072135, a low-penetrance variant for chronic lymphocytic leukaemia","volume":"162","author":"Sava","year":"2013","journal-title":"Br J Haematol"},{"key":"2025071610113972900_CIT0009","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3324\/haematol.2023.283181","article-title":"Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations","volume":"109","author":"Liu","year":"2024","journal-title":"Haematologica"},{"key":"2025071610113972900_CIT0010","doi-asserted-by":"publisher","first-page":"885150","DOI":"10.3389\/fonc.2022.885150","article-title":"Distinct age-related clinical features and risk assessment in Chinese with chronic lymphocytic leukemia","volume":"12","author":"Tian","year":"2022","journal-title":"Front Oncol"},{"key":"2025071610113972900_CIT0011","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.blre.2014.12.001","article-title":"The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology","volume":"29","author":"Yang","year":"2015","journal-title":"Blood Rev"},{"key":"2025071610113972900_CIT0012","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/CM9.0000000000001811","article-title":"Chronic lymphocytic leukemia in China","volume":"135","author":"Gale","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"2025071610113972900_CIT0013","doi-asserted-by":"publisher","first-page":"20520","DOI":"10.18632\/oncotarget.7819","article-title":"Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia","volume":"7","author":"Marinelli","year":"2016","journal-title":"Oncotarget"},{"key":"2025071610113972900_CIT0014","doi-asserted-by":"publisher","first-page":"25455","DOI":"10.18632\/oncotarget.16037","article-title":"Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients","volume":"8","author":"Chan","year":"2017","journal-title":"Oncotarget"},{"key":"2025071610113972900_CIT0015","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1038\/s41375-021-01124-5","article-title":"High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia","volume":"35","author":"Yi","year":"2021","journal-title":"Leukemia"},{"key":"2025071610113972900_CIT0016","doi-asserted-by":"publisher","first-page":"abs\/2001.09765","DOI":"10.48550\/arXiv.2001.09765","article-title":"Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research","author":"Birnbaum","year":"2020","journal-title":"ArXiv"},{"key":"2025071610113972900_CIT0017","article-title":"Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma","year":"2020","journal-title":"medRxiv"},{"key":"2025071610113972900_CIT0018","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3324\/haematol.2016.157552","article-title":"Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications","volume":"102","author":"Wu","year":"2017","journal-title":"Haematologica"},{"key":"2025071610113972900_CIT0019","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/hmg\/ddq044","article-title":"Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus","volume":"19","author":"Crowther-Swanepoel","year":"2010","journal-title":"Hum Mol Genet"},{"key":"2025071610113972900_CIT0020","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1600-0609.2010.01518.x","article-title":"Genetic susceptibility for chronic lymphocytic leukemia among Chinese in Hong Kong","volume":"85","author":"Lan","year":"2010","journal-title":"Eur J Haematol"},{"key":"2025071610113972900_CIT0021","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1084\/jem.20040544","article-title":"Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia","volume":"200","author":"Messmer","year":"2004","journal-title":"J Exp Med"},{"key":"2025071610113972900_CIT0022","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1084\/jem.20121801","article-title":"A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi","volume":"210","author":"Hoogeboom","year":"2013","journal-title":"J Exp Med"},{"key":"2025071610113972900_CIT0023","doi-asserted-by":"publisher","first-page":"825645","DOI":"10.3389\/fpubh.2022.825645","article-title":"The Epidemiological Pattern and Co-infection of Influenza A and B by Surveillance Network From 2009 to 2014 in Anhui Province, China","volume":"10","author":"He","year":"2022","journal-title":"Front Public Health"},{"key":"2025071610113972900_CIT0024","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1056\/NEJMe2302721","article-title":"Inhibiting BTK in Chronic Lymphocytic Leukemia","volume":"389","author":"Kater","year":"2023","journal-title":"N Engl J Med"},{"key":"2025071610113972900_CIT0025","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"key":"2025071610113972900_CIT0026","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"2025071610113972900_CIT0027","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/ajh.25259","article-title":"Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-na\u00efve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies","volume":"93","author":"Robak","year":"2018","journal-title":"Am J Hematol"},{"key":"2025071610113972900_CIT0028","doi-asserted-by":"publisher","first-page":"e14258","DOI":"10.1111\/ijcp.14258","article-title":"Epidemiology, treatment patterns and survival of chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL) in Taiwan, 2006-2015","volume":"75","author":"Ko","year":"2021","journal-title":"Int J Clin Pract"},{"key":"2025071610113972900_CIT0029","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev-publhealth-031816-044247","article-title":"China\u2019s Health Reform Update","volume":"38","author":"Liu","year":"2017","journal-title":"Annu Rev Public Health"},{"key":"2025071610113972900_CIT0030","doi-asserted-by":"publisher","first-page":"e2225973","DOI":"10.1001\/jamanetworkopen.2022.25973","article-title":"Overall survival benefits of cancer drugs approved in China from 2005 to 2020","volume":"5","author":"Zhang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025071610113972900_CIT0031","doi-asserted-by":"publisher","first-page":"1184395","DOI":"10.3389\/fimmu.2023.1184395","article-title":"Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China","volume":"14","author":"Yan","year":"2023","journal-title":"Front Immunol"},{"key":"2025071610113972900_CIT0032","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"key":"2025071610113972900_CIT0033","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLLIPIwg","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025071610113972900_CIT0034","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1200\/JCO.2010.33.9002","article-title":"Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia","volume":"29","author":"Wierda","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf181\/63546371\/oyaf181.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf181\/63546371\/oyaf181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf181\/63546371\/oyaf181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T14:11:46Z","timestamp":1752675106000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf181\/8171576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf181","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"oyaf181"}}